Business of the House

Danny Kruger Excerpts

Thursday 18th November 2021 Commons Chamber

[Mr Rees-Mogg]

I am grateful to the hon. Gentleman for raising this issue again. It has been a problem for some of my own constituents too, and I have therefore raised it at a constituency level as well as on behalf of the House. As I have said before, one of the very useful purposes of this session is that, if there is a general problem that gets raised by several hon. and right hon. Members, that gives me the opportunity to take it up. The DWP had hoped that the problem would be sorted by now, but I am hearing that it is not. I will therefore take it up with the DWP again and try to provide more information for the House on what progress is being made.

[Danny Kruger (Devizes) (Con)]

As chair of the all-party parliamentary group on prescribed drug dependence, I pay tribute to Dr Anne Guy, Dr James Davies and Luke Montague for their support for this really important work. Dr Davies recently published research showing that the NHS spends £500 million a year on unnecessary and habit-forming drugs, mostly antidepressants, that people should not be on any more. Does my right hon. Friend agree that this really needs attention, and will he find time for a debate on the over-prescription of habit-forming drugs?

[Mr Rees-Mogg]

This is a matter of considerable concern and my hon. Friend is right to raise it in this House. On 22 September the Government published “Good for you, good for us, good for everybody”, a review of over-prescribing commissioned by the Secretary of State and conducted by the chief pharmaceutical officer for England, Dr Keith Ridge, that sets out action to reduce patient harm by reducing unnecessary prescribing. A three-year national over-prescribing programme is being established to lead on implementation of the 20 recommendations in the review. A new national clinical director for prescribing, one of the review’s key recommendations, is currently being recruited to drive cross-system implementation and provide the clinical leadership for the programme. So I can reassure my hon. Friend that things are happening. As regards a debate, the Chairman of the Backbench Business Committee is paying close attention to our proceedings, and I direct my hon. Friend in that direction in the first instance.